SAN FRANCISCO--(BUSINESS WIRE)--Osteologix, Inc. (OTCBB: OLGX), a specialty pharmaceutical company, announced today that data from a Phase II clinical study of NB S101 (strontium malonate) was presented at the European Calcified Tissue Society’s 35th Annual Meeting in Barcelona, Spain.
